These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23643683)

  • 21. Recommendations for vaccination in patients with multiple sclerosis who are eligible for immunosuppressive therapies: Spanish consensus statement.
    Otero-Romero S; Rodríguez-García J; Vilella A; Ara JR; Brieva L; Calles C; Carmona O; Casanova V; Costa-Frossard L; Eichau S; García-Merino JA; Garcia-Vidal C; González-Platas M; Llaneza M; Martínez-Ginés M; Meca-Lallana JE; Prieto JM; Rodríguez-Antigüedad A; Tintoré M; Blanco Y; Moral E;
    Neurologia (Engl Ed); 2021; 36(1):50-60. PubMed ID: 32561334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Immunosuppressive medication in multiple sclerosis].
    García Merino JA
    Rev Neurol; 2002 Dec 16-31; 35(12):1154-8. PubMed ID: 12497298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination therapy in multiple sclerosis.
    Fernández O
    J Neurol Sci; 2007 Aug; 259(1-2):95-103. PubMed ID: 17507031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Knowns and unknowns in the future of multiple sclerosis treatment.
    Stüve O
    J Neurol Sci; 2009 Dec; 287 Suppl 1():S30-6. PubMed ID: 20106346
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modern multiple sclerosis treatment - what is approved, what is on the horizon.
    Pilz G; Wipfler P; Ladurner G; Kraus J
    Drug Discov Today; 2008 Dec; 13(23-24):1013-25. PubMed ID: 18775508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Current state of research on multiple sclerosis].
    Lubina-Dabrowska N; Stepień A; Chalimoniuk M
    Pol Merkur Lekarski; 2013 Mar; 34(201):135-9. PubMed ID: 23700821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Recent therapeutic strategy for multiple sclerosis].
    Itoyama Y
    Rinsho Shinkeigaku; 2001 Dec; 41(12):1214-7. PubMed ID: 12235841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adherence to treatment in multiple sclerosis.
    Santolaya Perrín R; Fernández-Pacheco García Valdecasas M; Arteche Eguizabal L; Gema Pérez Pérez I; Muñoz Muñoz N; Ibarra Barrueta O; Callejón Callejón G
    Farm Hosp; 2012; 36(3):124-9. PubMed ID: 21798780
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent developments in approved and oral multiple sclerosis treatment and an update on future treatment options.
    Wipfler P; Harrer A; Pilz G; Oppermann K; Trinka E; Kraus J
    Drug Discov Today; 2011 Jan; 16(1-2):8-21. PubMed ID: 21055477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Placebo-controlled clinical trials in multiple sclerosis: ethical considerations. National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MS.
    Lublin FD; Reingold SC
    Ann Neurol; 2001 May; 49(5):677-81. PubMed ID: 11357961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.
    Jacobs LD; Beck RW; Simon JH; Kinkel RP; Brownscheidle CM; Murray TJ; Simonian NA; Slasor PJ; Sandrock AW
    N Engl J Med; 2000 Sep; 343(13):898-904. PubMed ID: 11006365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comments on the contribution, "Immunomodulating staged therapy of multiple sclerosis by the Multiple Sclerosis Therapy Consensus Group"].
    Störh M
    Nervenarzt; 2002 Dec; 73(12):1207; author reply 1207. PubMed ID: 12599336
    [No Abstract]   [Full Text] [Related]  

  • 33. An IFNG polymorphism is associated with interferon-beta response in Spanish MS patients.
    Martínez A; de las Heras V; Mas Fontao A; Bartolomé M; de la Concha EG; Urcelay E; Arroyo R
    J Neuroimmunol; 2006 Apr; 173(1-2):196-9. PubMed ID: 16430971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expanded clinical trials of treatments for multiple sclerosis. The Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis of The National Multiple Sclerosis Society.
    Whitaker JN
    Ann Neurol; 1993 Dec; 34(6):755-6. PubMed ID: 8250523
    [No Abstract]   [Full Text] [Related]  

  • 35. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions.
    Krupp LB; Tardieu M; Amato MP; Banwell B; Chitnis T; Dale RC; Ghezzi A; Hintzen R; Kornberg A; Pohl D; Rostasy K; Tenembaum S; Wassmer E;
    Mult Scler; 2013 Sep; 19(10):1261-7. PubMed ID: 23572237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
    Bonafede MM; Johnson BH; Wenten M; Watson C
    Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of multiple sclerosis.
    Bosnjak-Pasić M; Vidrih B; Miskov S; Demarin V
    Acta Clin Croat; 2009 Sep; 48(3):349-53. PubMed ID: 20055262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implications for multiple sclerosis in the era of the Affordable Care Act: an evolving treatment paradigm.
    Brunetti L; Hunter SF
    Am J Manag Care; 2014 Dec; 20(11 Suppl):S228-41. PubMed ID: 25734888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Consensus definitions proposed for pediatric multiple sclerosis and related disorders.
    Krupp LB; Banwell B; Tenembaum S;
    Neurology; 2007 Apr; 68(16 Suppl 2):S7-12. PubMed ID: 17438241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumefactive multiple sclerosis requiring emergency craniotomy: case report and literature review.
    Munarriz PM; Castaño-Leon AM; Martinez-Perez R; Hernandez-Lain A; Ramos A; Lagares A
    Neurocirugia (Astur); 2013; 24(5):220-4. PubMed ID: 23582489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.